Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carboplatin
/ administration & dosage
Cisplatin
/ administration & dosage
Denmark
/ epidemiology
Deoxycytidine
/ administration & dosage
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Female
Follow-Up Studies
Humans
Imidazoles
/ administration & dosage
Longitudinal Studies
Male
Middle Aged
Patient Reported Outcome Measures
Prognosis
Prospective Studies
Quality of Life
Surveys and Questionnaires
Urinary Bladder Neoplasms
/ drug therapy
Gemcitabine
Patient-reported outcomes
chemotherapy
immunotherapy
quality of life
urinary bladder neoplasms
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
12
2019
revised:
17
02
2020
accepted:
19
02
2020
pubmed:
11
3
2020
medline:
15
5
2021
entrez:
11
3
2020
Statut:
ppublish
Résumé
Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient-reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL. BC patients in chemo- or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ-C30 and QLQ-BLM30 and 45 selected PRO-CTCAE items. Spearman's correlation analysis was performed for all PRO-CTCAE items and QLQ-C30 global QoL and subdomains. In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO-CTCAE items and the expected domain of QoL. The PRO-CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (r This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.
Sections du résumé
BACKGROUND
Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient-reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL.
METHODS
BC patients in chemo- or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ-C30 and QLQ-BLM30 and 45 selected PRO-CTCAE items. Spearman's correlation analysis was performed for all PRO-CTCAE items and QLQ-C30 global QoL and subdomains.
RESULTS
In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO-CTCAE items and the expected domain of QoL. The PRO-CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (r
CONCLUSIONS
This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.
Identifiants
pubmed: 32154663
doi: 10.1002/cam4.2958
pmc: PMC7196058
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Imidazoles
0
viniconazole
0
Deoxycytidine
0W860991D6
Carboplatin
BG3F62OND5
pembrolizumab
DPT0O3T46P
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3078-3087Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Pain Symptom Manage. 2018 Sep;56(3):421-429
pubmed: 29807157
Rev Med Chir Soc Med Nat Iasi. 2013 Jul-Sep;117(3):610-5
pubmed: 24502024
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
J Clin Oncol. 2004 Feb 15;22(4):714-24
pubmed: 14966096
Health Qual Life Outcomes. 2019 Jan 22;17(1):20
pubmed: 30670040
Cancer Med. 2020 May;9(9):3078-3087
pubmed: 32154663
Clin Interv Aging. 2015 Jun 10;10:939-49
pubmed: 26089655
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol Focus. 2020 Jan 15;6(1):26-30
pubmed: 30858072
Bladder Cancer. 2016 Jul 27;2(3):329-340
pubmed: 27500200
J Clin Oncol. 2014 Jan 20;32(3):199-205
pubmed: 24344222
Acta Oncol. 2019 May;58(5):596-602
pubmed: 30702003
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28423407
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Lancet. 2009 Jul 18;374(9685):239-49
pubmed: 19520422
J Patient Rep Outcomes. 2019 Aug 22;3(1):56
pubmed: 31440865
Qual Life Res. 2016 Mar;25(3):525-34
pubmed: 26790427
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
Value Health. 2018 Jun;21(6):742-747
pubmed: 29909880
Qual Life Res. 2016 May;25(5):1295-302
pubmed: 26584811
BJU Int. 2003 Mar;91(4):325-30; discussion 330
pubmed: 12603405
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Int J Cardiol. 2016 Jan 1;202:676-84
pubmed: 26453816